47 patients hospitalized for COVID treatment received either boswellia or a placebo for 2 weeks.
Results, versus the placebo group: the patients treated with boswellia had better oxygen saturation levels.
Had 42% lower levels of inflammatory markers.
Had hospital stays 25% shorter.
Additionally, every patient in the boswellia group who lost their sense of taste and smell had significant improvement, while several people in the placebo group with these symptoms had no improvement.